Tuning protein synthesis for cancer therapy.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-02-22 DOI:10.1080/23723556.2021.1884034

John R P Knight, Owen J Sansom

引用次数: 0

Abstract

~50% of colorectal cancers have an activating mutation in KRAS (encoding the KRAS proto-oncogene) and remain difficult to target in the clinic. We have recently shown that activation of KRAS protein alters the regulation of mRNA translation, increasing total protein synthesis, and maintaining elevated c-MYC (MYC proto-oncogene) expression. Targeting these pathways downstream of KRAS reveals a striking dependency that has potential for clinical translation.

Abstract Image

查看原文本刊更多论文

调控蛋白质合成以治疗癌症

~约 50% 的结直肠癌都有 KRAS（编码 KRAS 原癌基因）激活突变，但在临床上仍难以实现靶向治疗。我们最近发现，KRAS 蛋白的活化改变了 mRNA 翻译的调控，增加了蛋白质合成总量，并维持了 c-MYC（MYC 原癌基因）表达的升高。以 KRAS 下游的这些通路为靶点，揭示了一种显著的依赖关系，这种关系有可能转化为临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.